Core Viewpoint - The stock of Haisco Pharmaceutical Group Co., Ltd. has experienced fluctuations, with a year-to-date increase of 53.27% but a recent decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, Haisco achieved a revenue of 2 billion yuan, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million yuan [2]. - Cumulatively, Haisco has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of Haisco's shareholders increased by 25.93% to 11,400, while the average circulating shares per person decreased by 28.64% to 42,147 shares [2]. - The top ten circulating shareholders include several funds, with notable increases in holdings from China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [3]. Stock Market Activity - On October 13, Haisco's stock price fell by 2.05% to 50.55 yuan per share, with a trading volume of approximately 54.66 million yuan and a turnover rate of 0.22% [1]. - The stock's market capitalization stands at 56.612 billion yuan, with a net inflow of main funds amounting to 2.05 million yuan [1].

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Haishike Pharmaceutical Group, including stock price movements and market capitalization [1][2] - As of September 25, Haishike's stock price increased by 2.07% to 56.17 CNY per share, with a total market capitalization of 629.06 billion CNY [1] - Year-to-date, Haishike's stock has risen by 70.32%, with a 2.59% increase over the last five trading days and a 27.57% increase over the last 60 days [1] Group 2 - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the last three years [3] - As of June 30, 2025, the number of Haishike's shareholders increased by 25.93% to 11,400, while the average number of circulating shares per shareholder decreased by 28.64% to 42,147 shares [2][3] Group 3 - Haishike's main business segments include anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1] - The company is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, with involvement in various concept sectors such as Helicobacter pylori, hypertension treatment, and innovative drugs [1] - Notable institutional shareholders include China Europe Medical Health Mixed Fund and ICBC Frontier Medical Stock Fund, with significant increases in their holdings [3]

Group 1 - The core viewpoint of the news is that Haikang Technology's stock has seen a significant increase, with a rise of 5.15% to 55.38 CNY per share, and a total market capitalization of 62.021 billion CNY [1] - Haikang Technology, established on August 26, 2005, and listed on January 17, 2012, specializes in the research, development, production, and sales of chemical pharmaceuticals [1] - The main revenue composition of Haikang Technology includes anesthetic products (39.81%), cooperative product-related income (23.59%), other indications (17.02%), parenteral nutrition (10.32%), antiemetics for tumors (8.15%), and other supplementary income (0.86%) [1] Group 2 - Among the top ten circulating shareholders of Haikang Technology, a fund under China Europe Fund has increased its holdings by 5.3574 million shares, bringing its total to 21.2763 million shares, which accounts for 4.42% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has achieved a year-to-date return of 28.95% and a one-year return of 48.76% [2] - The fund manager, Ge Lan, has a tenure of 10 years and 242 days, with a total fund size of 39.908 billion CNY, achieving a best return of 126.87% during her tenure [3]

Core Viewpoint - The stock of Haishike experienced a decline of 2.02% on September 16, with a trading price of 55.31 yuan per share and a total market capitalization of 61.943 billion yuan. The company has seen a year-to-date stock price increase of 67.71% but has faced recent declines over the past five and twenty trading days [1]. Financial Performance - As of June 30, Haishike reported a revenue of 2.001 billion yuan for the first half of 2025, reflecting a year-on-year growth of 18.63%. However, the net profit attributable to shareholders decreased by 21.79% to 129 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Structure - The number of shareholders for Haishike increased by 25.93% to 11,400 as of June 30, with an average of 42,147 circulating shares per shareholder, a decrease of 28.64% [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A, which increased its holdings by 5.3574 million shares, and Industrial Bank's Frontier Medical Stock A, which increased its holdings by 5.4 million shares [3].

Core Viewpoint - The stock of Haishike experienced a decline of 2.03% on September 15, 2023, with a current price of 56.90 CNY per share and a total market capitalization of 63.723 billion CNY, despite a year-to-date increase of 72.53% [1] Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - Cumulative cash dividends since the A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per shareholder, down by 28.64% [2] - The top ten circulating shareholders include several funds, with notable increases in holdings by China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]

Company Overview - Haisco Pharmaceutical Group Co., Ltd. is located in Zedang Town, Shannan City, Tibet, and was established on August 26, 2005. The company was listed on January 17, 2012. Its main business involves the research, development, production, and sales of chemical pharmaceuticals. The revenue composition is 99.14% from the pharmaceutical industry and 0.86% from other sources [1]. Stock Performance - As of September 5, Haisco's stock price decreased by 2.04%, trading at 56.10 CNY per share, with a total market capitalization of 62.827 billion CNY. The stock has increased by 70.10% year-to-date, with a 1.15% increase over the last five trading days, a 5.65% decrease over the last 20 days, and a 20.78% increase over the last 60 days [1]. Financial Performance - For the first half of 2025, Haisco reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%. However, the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. Shareholder Information - As of June 30, 2025, Haisco had 11,400 shareholders, an increase of 25.93% from the previous period. The average number of tradable shares per shareholder decreased by 28.64% to 42,147 shares [2]. Dividend Distribution - Haisco has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, several funds increased their holdings, including China Europe Medical Health Mixed A, which holds 21.2763 million shares, an increase of 5.3574 million shares. Other funds also saw increases, while one fund reduced its holdings [3].

中信证券股份有限公司 经中国证券监督管理委员会《关于核准海思科医药集团股份有限公司非公开 发行股票的批复》（证监许可〔2022〕869 号）核准，公司于 2023 年 2 月 10 日 非公开发行人民币普通股（A 股）股票 40,000,000 股，发行价格为 20.00 元/股， 募 集 资 金 总 额 为 人 民 币 800,000,000.00 元 ， 扣 除 各 项 发 行 费 用 人 民 币 上述募集资金到位情况已经信永中和会计师事务所（特殊普通合伙）审验，于 募集资金验资报告》（XYZH/2022CDAA5B0008）。公司开立了募集资金专项账户， 对上述募集资金进行专户存储，并与保荐机构、存放募集资金的商业银行签署了 募集资金监管协议。 二、募投项目情况 鉴于公司 2020 年度非公开发行股票募集资金投资项目中的新药研发项目均 已取得药品注册证书/补充申请批准通知书且需支付的部分合同尾款也已基本支 付完毕，补充流动资金及偿还银行贷款也已实施完毕，公司决定将 2020 年度非 公开发行股票募集资金投资项目予以整体结项。公司于 2025 年 1 月 3 日召开第 五届董事会第二十一次会议、第五届监事 ...

Summary of Key Points Core Viewpoint - The company, Haishike, announced a plan for a major shareholder to reduce their stake in the company, which may impact the stock price and investor sentiment. The company is also in the process of raising funds for new drug development and working capital through a specific stock issuance. Group 1: Shareholder Actions - The controlling shareholder's associate, Shen Ping, plans to reduce their holdings by up to 10.37 million shares, representing a maximum of 0.926% of the total share capital within three months after the announcement [1] - The estimated cash amount from this reduction, based on the closing price of 48.2 yuan per share, is approximately 500 million yuan [1] - As of the announcement date, the controlling shareholder, Wang Junmin, holds 35.68% of the shares, while Shen Ping holds 4.43%, totaling 40.11% for the couple [1] Group 2: Financial Performance and Projections - In 2024, Haishike's revenue is projected to be 3.721 billion yuan, reflecting a year-on-year growth of 10.92%, with a net profit attributable to shareholders of 395 million yuan, up 34% [4] - For the first quarter of 2025, the company reported revenue of 892 million yuan, an increase of 18.6% year-on-year, but the net profit attributable to shareholders decreased by 49.31% to 46.61 million yuan [5] Group 3: Fundraising and Investment Plans - The company plans to raise up to 1.365 billion yuan through a specific stock issuance, with funds allocated for new drug research and development and to supplement working capital [3] - The total investment for the new drug development project is approximately 965.26 million yuan, while 400 million yuan is earmarked for working capital [4]

海思科医药集团股份有限公司 上市公司名称：海思科医药集团股份有限公司 股票简称：海思科 股票代码：002653 股票上市地点：深圳证券交易所 信息披露义务人1：王俊民 信息披露义务人2：范秀莲 信息披露义务人3：郑伟 住所/通讯地址：四川省成都市温江区百利路136号 股份变动性质：本次披露系三位信息披露义务人解除一致行动关系，持 股数不再合并计算所致，不涉及各自持股数量的变动。 签署日期：二〇二五年三月 一、信息披露义务人依据《中华人民共和国证券法》、《上市公司收购管理办 法》、《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告 书》及相关法律法规编写本权益变动报告书(以下简称"本报告书")。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发 行证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在海思科医药集团股份有限公司拥有权益的股 份变动情况。 四、截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务人没 有通过任何其他方式增加或减少其在海思科医药集团股 ...

海思科医药集团股份有限公司 证券代码：002653 证券简称：海思科 公告编号：2025-039 关于相关股东解除一致行动关系 暨控股股东、实际控制人变更的提示性公告 公司股东王俊民、范秀莲、郑伟保证向公司提供的信息披露内容的 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 重要内容提示： 息一致。 东/实际控制人之一郑伟已于 2024 年 2 月退休，此后郑伟未在公司担任任何职务， 亦未参与公司的经营管理。经王俊民、范秀莲、郑伟三方协商一致，于 2025 年 三方解除一致行动关系。 秀莲、郑伟变更为王俊民。 亦不会对公司控制权的稳定性、日常生产经营产生重大影响。 证券交易所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人 员减持股份》第六条、第七条有关控股股东、实际控制人不得减持公司股份的情 形等有关法律法规及规范性文件的相关规定。范秀莲、郑伟作为持股 5%以上的 大股东，其股份变动仍将严格遵守《中华人民共和国证券法》《上市公司收购管 理办法》《上市公司股 ...